Investigation of peanut oral immunotherapy with CpG/peanut nanoparticles in a murine model of peanut allergy

Journal of Allergy and Clinical Immunology

Volumn 138, Issue 2, 2016, Pages 536-543.e4

  Srivastava, Kamal D ^a,b   Siefert, Alyssa ^c   Fahmy, Tarek M ^c,d   Caplan, Michael J ^d   Li, Xiu Min ^a,b   Sampson, Hugh A ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Immunology and Jaffe Institute for Food Allergy   (United States)

^c Yale University   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

anaphylaxis; IgE; immunotherapy; mice; nanoparticle; Peanut allergy

Indexed keywords

CHOLERA TOXIN; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; HISTAMINE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; PEANUT EXTRACT; POLYGLACTIN; TOLL LIKE RECEPTOR; ALLERGEN; CYTOKINE; IMMUNOGLOBULIN G; LACTIC ACID; NANOPARTICLE; PLANT EXTRACT; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ALLERGIC REACTION; ANAPHYLAXIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY TEMPERATURE; CELL CULTURE; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTACT SENSITIZATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTAMINE BLOOD LEVEL; HYPOTHERMIA; IMMUNOGLOBULIN BLOOD LEVEL; MOUSE; NONHUMAN; ORAL IMMUNOTHERAPY; PEANUT ALLERGY; PRIORITY JOURNAL; SPLEEN CELL; SYMPTOM ASSESSMENT; THERAPY EFFECT; ADVERSE EFFECTS; ANIMAL; ARACHIS; BLOOD; CHEMISTRY; DESENSITIZATION; DISEASE MODEL; IMMUNIZATION; IMMUNOLOGY; METABOLISM; PEANUT HYPERSENSITIVITY; PROCEDURES;

ALLERGENS; ANIMALS; ARACHIS; CYTOKINES; DESENSITIZATION, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; FEMALE; HISTAMINE; IMMUNIZATION; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; LACTIC ACID; MICE; NANOPARTICLES; PEANUT HYPERSENSITIVITY; PLANT EXTRACTS; POLYGLYCOLIC ACID;

EID: 84964620724     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2016.01.047     Document Type: Article

References (47)

1. 1 Skripak, J.M., Wood, R.A., Peanut and tree nut allergy in childhood. Pediatr Allergy Immunol 19 (2008), 368–373.
2. 2 Finkelman, F.D., Peanut allergy and anaphylaxis. Curr Opin Immunol 22 (2010), 783–788.
3. 3 Primeau, M.N., Kagan, R., Joseph, L., Lim, H., Dufresne, C., Duffy, C., et al. The psychological burden of peanut allergy as perceived by adults with peanut allergy and the parents of peanut-allergic children. Clin Exp Allergy 30 (2000), 1135–1143.
4. 4 Le, T.M., Lindner, T.M., Pasmans, S.G., Guikers, C.L., van, H.E., Bruijnzeel-Koomen, C.A., et al. Reported food allergy to peanut, tree nuts and fruit: comparison of clinical manifestations, prescription of medication and impact on daily life. Allergy 63 (2008), 910–916.
5. 5 Varshney, P., Jones, S.M., Scurlock, A.M., Perry, T.T., Kemper, A., Steele, P., et al. A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. J Allergy Clin Immunol 127 (2011), 654–660.
6. 6 Chin, S.J., Vickery, B.P., Kulis, M.D., Kim, E.H., Varshney, P., Steele, P., et al. Sublingual versus oral immunotherapy for peanut-allergic children: a retrospective comparison. J Allergy Clin Immunol 132 (2013), 476–478.e2.
7. 7 Anagnostou, K., Clark, A., King, Y., Islam, S., Deighton, J., Ewan, P., Efficacy and safety of high-dose peanut oral immunotherapy with factors predicting outcome. Clin Exp Allergy 41 (2011), 1273–1281.
8. 8 Blumchen, K., Ulbricht, H., Staden, U., Dobberstein, K., Beschorner, J., de Oliveira, L.C., et al. Oral peanut immunotherapy in children with peanut anaphylaxis. J Allergy Clin Immunol 126 (2010), 83–91.
9. 9 Greenhawt, M.J., Oral and sublingual peanut immunotherapy is not ready for general use. Allergy Asthma Proc 34 (2013), 197–204.
10. 10 Hofmann, A.M., Scurlock, A.M., Jones, S.M., Palmer, K.P., Lokhnygina, Y., Steele, P.H., et al. Safety of a peanut oral immunotherapy protocol in children with peanut allergy. J Allergy Clin Immunol 124 (2009), 286–291.
11. 11 Varshney, P., Steele, P.H., Vickery, B.P., Bird, J.A., Thyagarajan, A., Scurlock, A.M., et al. Adverse reactions during peanut oral immunotherapy home dosing. J Allergy Clin Immunol 124 (2009), 1351–1352.
12. 12 Sheikh, A., Nurmatov, U., Venderbosch, I., Bischoff, E., Oral immunotherapy for the treatment of peanut allergy: systematic review of six case series studies. Prim Care Respir J 21 (2012), 41–49.
13. 13 Nurmatov, U., Venderbosch, I., Devereux, G., Simons, F.E., Sheikh, A., Allergen-specific oral immunotherapy for peanut allergy. Cochrane Database Syst Rev, 9, 2012, CD009014.
14. 14 Sampson, H.A., Is peanut oral immunotherapy ready for use in clinical practice?. J Allergy Clin Immunol Pract 1 (2013), 15–21.
15. 15 Kumar, G., Shafiq, N., Malhotra, S., Drug-loaded PLGA nanoparticles for oral administration: fundamental issues and challenges ahead. Crit Rev Ther Drug Carrier Syst 29 (2012), 149–182.
16. 16 Hunter, Z., McCarthy, D.P., Yap, W.T., Harp, C.T., Getts, D.R., Shea, L.D., et al. A biodegradable nanoparticle platform for the induction of antigen-specific immune tolerance for treatment of autoimmune disease. ACS Nano 8 (2014), 2148–2160.
17. 17 Silva, A.L., Rosalia, R.A., Varypataki, E., Sibuea, S., Ossendorp, F., Jiskoot, W., Poly-(lactic-co-glycolic-acid)-based particulate vaccines: particle uptake by dendritic cells is a key parameter for immune activation. Vaccine 33 (2015), 847–854.
18. 18 Bayne, K., Developing guidelines on the care and use of animals. Ann N Y Acad Sci 862 (1998), 105–110.
19. 19 Srivastava, K.D., Bardina, L., Sampson, H.A., Li, X.M., Efficacy and immunological actions of FAHF-2 in a murine model of multiple food allergies. Ann Allergy Asthma Immunol 108 (2012), 351–358.
20. 20 Talbot, R.W., Foster, J.R., Hermon-Taylor, J., Grant, D.A., Induced mucosal penetration and transfer to portal blood of luminal horseradish peroxidase after exposure of mucosa of guinea pig small intestine to ethanol and lysolecithin. Dig Dis Sci 29 (1984), 1015–1022.
21. 21 Fahmy, T.M., Samstein, R.M., Harness, C.C., Mark, S.W., Surface modification of biodegradable polyesters with fatty acid conjugates for improved drug targeting. Biomaterials 26 (2005), 5727–5736.
22. 22 De Castro, C., Parrilli, M., Holst, O., Molinaro, A., Microbe-associated molecular patterns in innate immunity: extraction and chemical analysis of gram-negative bacterial lipopolysaccharides. Methods Enzymol 480 (2010), 89–115.
23. 23 Li, X.M., Serebrisky, D., Lee, S.Y., Huang, C.K., Bardina, L., Schofield, B.H., et al. A murine model of peanut anaphylaxis: T- and B-cell responses to a major peanut allergen mimic human responses. J Allergy Clin Immunol 106 (2000), 150–158.
24. 24 Srivastava, K.D., Kattan, J.D., Zou, Z.M., Li, J.H., Zhang, L., Wallenstein, S., et al. The Chinese herbal medicine formula FAHF-2 completely blocks anaphylactic reactions in a murine model of peanut allergy. J Allergy Clin Immunol 115 (2005), 171–178.
25. 25 Qu, C., Srivastava, K., Ko, J., Zhang, T.F., Sampson, H.A., Li, X.M., Induction of tolerance after establishment of peanut allergy by the food allergy herbal formula-2 is associated with up-regulation of interferon-gamma. Clin Exp Allergy 37 (2007), 846–855.
26. 26 Smit, J.J., Willemsen, K., Hassing, I., Fiechter, D., Storm, G., van Bloois, L., et al. Contribution of classic and alternative effector pathways in peanut-induced anaphylactic responses. PLoS One, 6, 2011, e28917.
27. 27 Bauer, S., Kirschning, C.J., Hacker, H., Redecke, V., Hausmann, S., Akira, S., et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci U S A 98 (2001), 9237–9242.
28. 28 Pali-Scholl, I., Szollosi, H., Starkl, P., Scheicher, B., Stremnitzer, C., Hofmeister, A., et al. Protamine nanoparticles with CpG-oligodeoxynucleotide prevent an allergen-induced Th2-response in BALB/c mice. Eur J Pharm Biopharm 85 (2013), 656–664.
29. 29 Sah, H., Thoma, L.A., Desu, H.R., Sah, E., Wood, G.C., Concepts and practices used to develop functional PLGA-based nanoparticulate systems. Int J Nanomedicine 8 (2013), 747–765.
30. 30 Kulis, M., Gorentla, B., Burks, A.W., Zhong, X.P., Type B CpG oligodeoxynucleotides induce Th1 responses to peanut antigens: modulation of sensitization and utility in a truncated immunotherapy regimen in mice. Mol Nutr Food Res 57 (2013), 906–915.
31. 31 Campbell, J.D., Kell, S.A., Kozy, H.M., Lum, J.A., Sweetwood, R., Chu, M., et al. A limited CpG-containing oligodeoxynucleotide therapy regimen induces sustained suppression of allergic airway inflammation in mice. Thorax 69 (2014), 565–573.
32. 32 Horner, A.A., Takabayashi, K., Beck, L., Sharma, B., Zubeldia, J., Baird, S., et al. Optimized conjugation ratios lead to allergen immunostimulatory oligodeoxynucleotide conjugates with retained immunogenicity and minimal anaphylactogenicity. J Allergy Clin Immunol 110 (2002), 413–420.
33. 33 Horner, A.A., Nguyen, M.D., Ronaghy, A., Cinman, N., Verbeek, S., Raz, E., DNA-based vaccination reduces the risk of lethal anaphylactic hypersensitivity in mice. J Allergy Clin Immunol 106 (2000), 349–356.
34. 34 Simons, F.E., Shikishima, Y., Van, N.G., Eiden, J.J., Hayglass, K.T., Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J Allergy Clin Immunol 113 (2004), 1144–1151.
35. 35 Senti, G., Johansen, P., Haug, S., Bull, C., Gottschaller, C., Muller, P., et al. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. Clin Exp Allergy 39 (2009), 562–570.
36. 36 Creticos, P.S., Schroeder, J.T., Hamilton, R.G., Balcer-Whaley, S.L., Khattignavong, A.P., Lindblad, R., et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 355 (2006), 1445–1455.
37. 37 Turcanu, V., Maleki, S.J., Lack, G., Characterization of lymphocyte responses to peanuts in normal children, peanut-allergic children, and allergic children who acquired tolerance to peanuts. J Clin Invest 111 (2003), 1065–1072.
38. 38 Demento, S.L., Bonafe, N., Cui, W., Kaech, S.M., Caplan, M.J., Fikrig, E., et al. TLR9-targeted biodegradable nanoparticles as immunization vectors protect against West Nile encephalitis. J Immunol 185 (2010), 2989–2997.
39. 39 Leonard, S.A., Martos, G., Wang, W., Nowak-Wegrzyn, A., Berin, M.C., Oral immunotherapy induces local protective mechanisms in the gastrointestinal mucosa. J Allergy Clin Immunol 129 (2012), 1579–1587.
40. 40 Jimenez-Saiz, R., Rupa, P., Mine, Y., Immunomodulatory effects of heated ovomucoid-depleted egg white in a BALB/c mouse model of egg allergy. J Agric Food Chem 59 (2011), 13195–13202.
41. 41 Burton, O.T., Logsdon, S.L., Zhou, J.S., Medina-Tamayo, J., Abdel-Gadir, A., Noval, R.M., et al. Oral immunotherapy induces IgG antibodies that act through FcgammaRIIb to suppress IgE-mediated hypersensitivity. J Allergy Clin Immunol 134 (2014), 1310–1317.
42. 42 Lutsiak, M.E., Kwon, G.S., Samuel, J., Biodegradable nanoparticle delivery of a Th2-biased peptide for induction of Th1 immune responses. J Pharm Pharmacol 58 (2006), 739–747.
43. 43 Diwan, M., Elamanchili, P., Cao, M., Samuel, J., Dose sparing of CpG oligodeoxynucleotide vaccine adjuvants by nanoparticle delivery. Curr Drug Deliv 1 (2004), 405–412.
44. 44 Silva, J.M., Videira, M., Gaspar, R., Preat, V., Florindo, H.F., Immune system targeting by biodegradable nanoparticles for cancer vaccines. J Control Release 168 (2013), 179–199.
45. 45 Kawakita, A., Shirasaki, H., Yasutomi, M., Tokuriki, S., Mayumi, M., Naiki, H., et al. Immunotherapy with oligomannose-coated liposomes ameliorates allergic symptoms in a murine food allergy model. Allergy 67 (2012), 371–379.
46. 46 Mondoulet, L., Dioszeghy, V., Larcher, T., Ligouis, M., Dhelft, V., Puteaux, E., et al. Epicutaneous immunotherapy (EPIT) blocks the allergic esophago-gastro-enteropathy induced by sustained oral exposure to peanuts in sensitized mice. PLoS One, 7, 2012, e31967.
47. 47 Reisacher, W.R., Liotta, D., Yazdi, S., Putnam, D., Desensitizing mice to ovalbumin through subcutaneous microsphere immunotherapy (SMITH). Int Forum Allergy Rhinol 1 (2011), 390–395.